Antitumor necrosis factor-induced neutropenia:: a case report with double positive rechallenges

被引：35
作者：
Montane, E.
Salles, M.
Barriocanal, A.
Riera, E.
Costa, J.
Tena, X.
机构：
[1] Hosp Germans Trias & Pujol, Dept Clin Pharmacol, Badalona 08916, Spain
[2] Univ Autonoma Barcelona, Dept Pharmacol Therapeut & Toxicol, Bellaterra, Spain
[3] Hosp Germans Trias & Pujol, Dept Rheumatol, Badalona 08916, Spain
[4] Univ Autonoma Barcelona, Dept Med, Bellaterra, Spain
来源：
CLINICAL RHEUMATOLOGY | 2007年 / 26卷 / 09期
关键词：
antitumor necrosis factor; etanercept; infliximab; neutropenia; positive rechallenge;
D O I：
10.1007/s10067-006-0415-y
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
A 50-year-old man with ankylosing spondylitis who developed neutropenia after treatment of etanercept, with two positive rechallenges, and after the first infliximab infusion, is described. Although leukopenia and neutropenia related to etanercept and infliximab have been described as rare adverse events from clinical trials data, their mechanism of action are unknown. This patient developed recurrent mild neutropenia after exposition of two different antitumor necrosis factors; therefore, it seems to be an adverse reaction related to the therapeutic group. Doctors should be aware of this potentially severe adverse effect in patients treated with antitumor necrosis factor.
引用
收藏
页码：1527 / 1529
页数：3
相关论文
共 14 条
[1]  
BERLINER N, 2004, AM SOC HEMATOL ED PR, P63
[2]   Adverse reactions to TNF-α inhibitors in rheumatoid arthritis [J].
Day, R .
LANCET, 2002, 359 (9306) :540-541
[3]  
Favalli EG, 2005, CLIN EXP RHEUMATOL, V23, P247
[4]   Results from a nationwide postmarketing cohort study of patients in Sweden treated with etanercept [J].
Feltelius, N ;
Fored, CM ;
Blomqvist, P ;
Bertilsson, L ;
Geborek, P ;
Jacobsson, LT ;
Lindblad, S ;
Lysholm, J ;
Rantapää-Dahlqvist, S ;
Saxne, T ;
Klareskog, L .
ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 (02) :246-252
[5]   Safety and efficacy of disease-modifying anti-rheumatic agents - Focus on the benefits and risks of etanercept [J].
Fleischmann, R ;
Iqbal, I ;
Nandeshwar, P ;
Quiceno, A .
DRUG SAFETY, 2002, 25 (03) :173-197
[6]   Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate [J].
Genovese, MC ;
Cohen, S ;
Moreland, L ;
Lium, D ;
Robbins, S ;
Newmark, R ;
Bekker, P .
ARTHRITIS AND RHEUMATISM, 2004, 50 (05) :1412-1419
[7]   Etanercept in treatment of Felty's syndrome [J].
Ghavami, A ;
Genevay, S ;
Fulpius, T ;
Gabay, C .
ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 (07) :1090-1091
[8]   Anti-tumour necrosis factor a therapy in rheumatoid arthritis: an update on safety [J].
Hyrich, KL ;
Silman, AJ ;
Watson, KD ;
Symmons, DPM .
ANNALS OF THE RHEUMATIC DISEASES, 2004, 63 (12) :1538-1543
[9]   Safety of tumour necrosis factor-α antagonists [J].
Khanna, D ;
McMahon, M ;
Furst, DE .
DRUG SAFETY, 2004, 27 (05) :307-324
[10]  
Malgarini RB, 2004, LANCET, V363, P1733, DOI 10.1016/S0140-6736(04)16264-8
12